Kasvu Therapeutics Raises €30M Series A for TrkB Neuroplastogen
Kasvu Therapeutics raised a €30 million Series A led by Hadean Ventures to move its TrkB-potentiating drug KTX-0141 through IND/CTA-enabling work and Phase 1/1b development.
investment-strategies
-
-
Numeral Raises $100M Series C for AI-Powered Sales Tax Compliance
Numeral raised a $100 million Series C led by Insight Partners, taking total funding to $157 million as it expands tax-compliance software beyond internet businesses.
-
Ema Raises $77M Series B to Scale Enterprise AI Employees
Ema raised a $77 million all-equity Series B led by Creaegis, with Accel, S32 and Prosus increasing their investments. Total funding is now $140 million.
-
Precision Neuroscience Closes $250M Series D for Its Brain Interface
Precision Neuroscience closed an oversubscribed $250 million Series D, bringing total capital raised to $430 million as it advances a minimally invasive cortical interface toward broader clinical use.
-
Enveda Closes $311M Series E for AI-Discovered Medicines
Enveda closed a $311 million Series E led by Catalio Capital Management to advance nature-derived drug candidates and expand its AI discovery platform. The company has now disclosed more than $845 million in funding.
-
TEKEVER’s $580M Series D Is a First Close at $6.4B
TEKEVER announced a $580 million first close of its Series D at a $6.4 billion valuation, led by UC Investments and Baillie Gifford. The capital is committed, but the round may add further closes.